anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
First and second volume data are collected in advance for the same region of a human body under examination. By performing volume rendering along the set direction of line of sight, a composite image of a first three-dimensional image based on the first volume data and a second three-dimensional image based on the second volume data is produced. The volume rendering is performed taking into consideration whether the trimming of the front region has been specified or not. In the volume rendering, by setting the initial position of a point of interest on the plane of projection or on the plane section indicated by a depth map according to whether the trimming of the front region has been specified or not, a three-dimension imaging region is varied. When the trimming of the front region has been specified, the initial position of the point of interest is set on the plane of projection. Otherwise, the depth map is examined for value D 1 (x,y) of the point of interest and, if the value is less than the maximum depth Dmax, the initial position of the point of interest is set on the plane section. That is, the depth is set to D 1 (x, y). If the value is greater than maximum depth Dmax, the initial position of the point of interest is set on the plane of projection. That is, the depth is initialized to 0.
Intermittent caloric restriction or fasting has numerous health effects including the reduction in numerous cardiovascular disease risk factors. The cellular programs activated by caloric restriction are similarly turned on in preclinical studies in response to a 24-hour fast. We have found that a beneficial effect of 24-hour fasting is that it blunts the activation of a component of the immune system, termed the Nod-like receptor family protein 3 (NLRP3) Inflammasome. This inflammasome, as a mediator of sterile inflammation, is associated with the development of diabetes and atherosclerosis. At the same time, we found that refeeding after the 24-hour fast significantly increased NLRP3 protein levels, IL-1Beta, and TNF signaling, and that fasting blunted the NLRP3 inflammasome response, in association with the activation of a fasting sensing protein called SIRT3. Interestingly, a recently discovered naturally occurring form of vitamin B3, called nicotinamide riboside (NR), has been found to activate SIRT3. We found that NR reproduces the NLRP3 inflammasome blunting effect of fasting when administered to primary human monocytes/macrophages in culture. Putting this together, it would be interesting to evaluate whether the administration of NR to human subjects would replicate the fasting blunting effect on the NLRP3 inflammasome. Interestingly, at the same time, it has recently been found, in a preclinical study, that the NLRP3 protein can orchestrate differentiation of naive T- cells into Th2 cells. We therefore propose to more broadly examine the effects of NR administration on myeloid and lymphoid cell biology in healthy volunteers.
The efficacy and safety of OXERVATE for the treatment of neurotrophic keratitis was studied in a total of 151 patients, evaluated in two 8-week, randomized, multi-center, double-masked, vehicle-controlled studies. Patients were randomized to OXERVATE, cenegermin-bkbj 10 mcg/mL, or vehicle in Study NGF0212, and OXERVATE or vehicle in Study NGF0214 dosed 6 times daily in the affected eye(s) for 8 weeks. In study NGF0212, only patients with unilateral disease were enrolled, while in study NGF0214 patients with bilateral disease were treated bilaterally. The mean age was 61 to 65 years (18-95). The majority of patients were female (approximately 61%).

Table 1 below summarizes the results for complete corneal healing defined as absence of staining of the corneal lesion and no persistent staining in the rest of the cornea after 8 weeks of treatment.

Table 1. Percentage of Patients with Complete Corneal Healing at Week 8

In patients who were healed after 8 weeks of treatment with OXERVATE, recurrences occurred in approximately 20% of patients in Study NGF0212 and 14% of patients in Study NGF0214.

The results of the mean change from baseline in corneal sensitivity inside the lesion after 8 weeks of treatment are summarized descriptively in Table 2. The mean changes in corneal sensitivity were not clinically significant in either study.

Table 2: Mean Corneal Sensitivity inside the Lesion: Baseline and Change from Baseline at Week 8
Home visitation is a prevention program for sociodemographically high risk, first-time mothers and their children that is designed to optimize maternal life course and child trajectories. Research indicates that maternal depression (1) is a significant problem in home visitation with up to 45% of mothers experiencing clinically elevated symptoms while only 14% receive treatment, and (2) can significantly interfere with the efficacy of home visitation. Moreover, maternal depression negatively impacts mother-child interactions and child functioning thus potentially precluding the dyad from fully benefiting from home visitation. To address the high rate of maternal depression in existing home visitation programs, In-Home Cognitive Behavior Therapy (IH-CBT) was developed through an R34 grant as a treatment for mothers in home visitation experiencing depression postpartum. IH-CBT consists of the core features of CBT that have been adapted to address the unique needs and challenges of mothers receiving home visitation. Findings from the R34 indicate that IH-CBT is highly effective at reducing depression, with 66.7% of depressed mothers no longer obtaining a diagnosis of MDD at the end of treatment in contrast to a rate of 24.3% in mothers receiving home visitation alone. In addition, mothers receiving IH-CBT reported increased social support and reduction in other psychiatric symptoms, much of which was maintained at 3 month follow-up. This study seeks to replicate IH-CBT with a larger sample, compare the treatment to a more rigorous control condition (Present-Centered Therapy-PCT), and extend follow-up to 18 months in order to determine relapse rate. There is mixed evidence regarding the long-term effectiveness of home visitation on depressed mothers and their children-critical outcomes that, if adequately demonstrated, would significantly enhance the public health implications of home visitation. Accordingly, the study also seeks to examine the impact of IH-CBT and recovery from depression on parenting and children. Specifically, 220 mothers who are enrolled in home visitation will be recruited through initial screening and subsequent diagnosis of MDD. Subjects will be randomly assigned to IH-CBT + home visitation or PCT + home visitation. Both IH-CBT and PCT will be implemented in 15 sessions with two booster sessions provided 1 and 2 months after treatment. Measures of depression, psychiatric comorbidity, adaptive functioning, social support, parenting, and child functioning will be administered at pre-treatment, post-treatment, and at 6, 12 and 18 month follow-ups after post-treatment. It is hypothesized that IH-CBT will be superior to PCT in (1) recovery from depression, (2) risk of relapse and recurrence, and (3) increasing social support and reducing overall psychiatric symptomatology. In addition, mothers who recover from depression will show improvements in parenting and the mother-child relationship, and their children will achieve improved cognitive, social, emotional, and biologic outcomes, relative to non-recovered mothers and their offspring.
Patients \>40 years of age with a histologically confirmed diagnosis of primary colorectal cancer and a planned surgical resection of the primary tumour. The Natural Killer Cell Activity Assay (NKA) will be measured at various perioperative time points with a blood test.
<P>PROBLEM TO BE SOLVED: To prepare a cosmetic which has an excellent skin unevenness-correcting effect for covering the small wrinkles and pores of the skin, can give a natural finish without deteriorating a bare skin appearance and a transparent appearance, gives a highly good sense of use, and has a highly good effect-retaining property.  <P>SOLUTION: This oily cosmetic is characterized by containing a silicone oil and a silicone-gelling agent as base materials, and further containing (A) silicone powder comprising a crosslinked silicone / a net-like silicone block copolymer, and (B) the powder of a crosslinked polymethyl methacrylate (PMMA). It is preferable that the mass ratio of the silicone powder (A) : PMMA powder is 7 : 3 to 4 : 1. Further, It is preferable that (C) fine titanium dioxide particles are contained in the cosmetic in an amount of 0.01 to 4 mass %. The silicone-gelling agent is preferably a crosslinked organopolysiloxane.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
NEW MATERIAL:The compound of formula [X is Met(OH) or Ala; Y is Gly-OC2 H5, NHNH2, etc.; when X is Ala, Y is Gly-OC2H5]. EXAMPLE:L-Tyrosyl-D-methioninesulfoxide-L-phenylalanyl-glycyl-ethyl ester. USE:Useful as drugs such as analgesic. It has agonistic activity to opiate receptor. PREPARATION:The compound of formula can be prepared e.g. by reacting an amino-protected amino acid or peptide or its reactive derivative at the carboxyl group (e.g. acid azide, mixed acid anhydride, etc.) with an amino acid or peptide, and removing the protecting group from the reaction product. The reaction is carried out usually in a solvent such as THF, chloroform, dichloromethane, etc. at about -50-+50 deg.C.
Patients receive dinaciclib IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Patients should prime QVAR by actuating into the air twice before using for the first time or if QVAR has not been used for over ten days. Avoid spraying in the eyes or face when priming QVAR. QVAR is a solution aerosol, which does not require shaking. Consistent dose delivery is achieved, whether using the 40 or 80 mcg strengths, due to proportionality of the two products (i.e., two actuations of 40 mcg strength should provide a dose comparable to one actuation of the 80 mcg strength).

QVAR should be administered by the oral inhaled route in patients 5 years of age and older. Use of QVAR with a spacer device in children less than 5 years of age is not recommended (see PRECAUTIONS, Pediatric Use). The onset and degree of symptom relief will vary in individual patients. Improvement in asthma symptoms should be expected within the first or second week of starting treatment, but maximum benefit should not be expected until 3-4 weeks of therapy. For patients who do not respond adequately to the starting dose after 3-4 weeks of therapy, higher doses may provide additional asthma control. The safety and efficacy of QVAR when administered in excess of recommended doses has not been established.

As with any inhaled corticosteroid, physicians are advised to titrate the dose of QVAR downward over time to the lowest level that maintains proper asthma control. This is particularly important in children since a controlled study has shown that QVAR has the potential to affect growth in children. Patients should be instructed on the proper use of their inhaler.
BACKGROUND: The purpose of this study was to quantify how much of the burden of visual impairment (VI) and unmet need in Talagang, identified by Rapid Assessment of Avoidable Blindness (RAAB) survey data, has been addressed by Community Eye Health (CEH) programme efforts.
METHODS: A RAAB survey was carried out in November 2018, with 2,824 participants in Talagang Tehsil, Punjab, Pakistan, aged 50 and over. Census data were used to extrapolate survey data to the population. Alongside this, a CEH programme was launched, consisting of community eye screening, and onward referral to rural health centres, secondary or tertiary ophthalmological services, as required. This health intervention aimed to address the eye care needs surfaced by the initial survey. From 2018 to 2022, 30,383 people aged 50 or over were screened; 14,054 needed referral to further steps of the treatment pathway and more detailed data collection. Programme data were compared to estimates of population unmet needs. Main outcome measures were prevalence of VI, and proportion of need met by CEH Programme, by cause and level of VI.
RESULTS: Among those aged 50 and over, 51.0% had VI in at least one eye. The leading causes were cataract (46.2%) and uncorrected refractive error (URE) (25.0%). In its first four years, the programme reached an estimated 18.3% of the unmet need from cataract, and 21.1% of URE, equally in both men and women.
CONCLUSIONS: Robustly collected survey and programme data can improve eye health planning, monitoring and evaluation, address inequities, and quantify the resources required for improving eye health. This study quantifies the time required to reach eye health needs at the community level.
PURPOSE:To provide a powdery make-up cosmetic giving little compressive feeling to the skin, having excellent moist feeling and capable of forming durable make-up. CONSTITUTION:A powdery base is mixed with a pigment coated with a monoacyl phospholipid of formula I or formula II (R is CO-C15H31 or CO-C17H35; X is group of formula III to formula V), e.g. 1-palmitoyl-3-glycerol phosphorylcholine or 2-stearoyl-3-glycerylphosphoryl ethanolamine. The amount of the pigment is 80-100wt.% based on the make-up cosmetic and that of the applied monoacyl-type phospholipid is preferably 0.1-5.0wt.% based on the total amount of the treated powder. The powdery base is e.g. extender pigment, high molecular powder pigment, inorganic colored pigment, organic synthetic colorant and natural pigment.
BACKGROUND: Although chemoradiotherapy is an effective treatment for esophageal cancer, its feasibility in esophageal cancer with cirrhosis remains largely unclear.
METHODS: We retrospectively studied 11 patients with superficial esophageal cancer with liver cirrhosis (Child-Pugh score ≤8) who underwent radical chemoradiotherapy from four centers, and the overall survival rate, local control rate and adverse events at 1 and 3 years were explored.
RESULTS: The median age of the included patients was 67 years (Inter-Quartile Range 60-75 years). Complete response was observed in most patients (n = 10, 90.9%), and the remaining patient was unevaluable. The 1- and 3-year overall survival and local control rates were 90.9% and 90.9%, and 72.7% and 63.6%, respectively. Hematotoxicity was a common adverse reaction, and seven patients developed radiation esophagitis, with grade 3-4 observed in two cases. All cases of radiation dermatitis (n = 4) and radiation pneumonia (n = 2) were grade 1-2. Gastrointestinal bleeding occurred in two patients, including one with grade 1-2 bleeding, and one died.
CONCLUSION: Radical chemoradiotherapy is a potential treatment option for patients with superficial esophageal cancer complicated with cirrhosis. However, it can increase the risk of bleeding, which warrants prompt recognition and intervention.
This strategy will be implemented at all clinics (n=28) within this arm for 18 months. Study staff will encourage providers at each of the clinics to screen all consenting patients attending the clinic, regardless of the original reason for clinic presentation. Upon presenting for care (e.g., while waiting for their healthcare provider), patients will be informed about the study and screened for cough of any duration, fever, weight loss, or night sweats. Participants who are symptomatic and provide a sputum specimen (according to the clinic standard of care) will be given a study flyer informing them that they may be contacted by study staff, and a brief summary of the study. Per standard of care, all sputum samples will be sent to the local National Health Laboratory Service laboratory for Xpert testing.
NEW MATERIAL:A peptide (salt) expressed by the formula (X is H, amino or acetylamino). USE:A preventive or treating agent for carious teeth and osteopathy. PREPARATION:For example, a benzhydrylamine polymer is used and linked to amino acids starting from an amino acid having protected alpha-amino group at the C-terminal in the presence of a condensing agent according to the amino acid sequence of a peptide and the amino-protecting groups are removed. The above-mentioned operation is repeated to afford the aimed polymer linked to peptide amide. The resultant polymer is then treated with trifluoroacetic acid, etc., to remove the protecting groups and an acetylating agent, such as acetic anhydride, is reacted in the presence of a tertiary amine to acetylate the alpha-amino group at the N-terminal amino acid. The obtained product is subsequently treated with anhydrous hydrogen fluoride, etc., to eliminate the peptide from the polymer and afford the aimed peptide expressed by the formula.
In the era of COVID-19, there has been much speculation about the risks and benefits of cannabis use for immune support. It is well known that the endocannabinoid system plays a role in the regulation of the immune response and its role in inflammation reduction may be useful in terms of a potential adjunctive therapy for acute infection. Cannabis products vary widely in their composition and may have a varying effect based on the strain and the associated terpenes. Here, we aim to track cannabis and hemp usage during an acute infection to understand it's safety and effects in a symptomatic population.

Given the fast and widespread acceptance and use of cannabis products in the US market, commercial use has outpaced randomized controlled trials (RCTs). Thus, carefully designed observational studies are important to understand how these products are affecting consumers. Prospective observational designs allow for real-world examinations of commercialized products with similar effect sizes to RCTs. Although observational designs have some drawbacks, a review covering 1,583 meta-analyses across 228 medical conditions compared the effect sizes from RCTs with those from observational studies for the same medical conditions and found no differences between the two. (1) These data provide evidence that a carefully designed observational study can help us better understand the effects of commonly used products such as cannabis edibles. The aim of this observational study is to evaluate the safety and associated effects of commercially available cannabis products in the US in symptomatic individuals seeking them for immune support.
PURPOSE:To provide a slip printer capable of directly printing data containing a bar code of a patient's ID number on a label to enhance the operating efficiency in making an entry of a patient's ID number, a patient's name, a date of taking blood/urine, and the like in a blood/urine vessel and reduce occurence of an errors. CONSTITUTION:In the application to a slip printer used in a hospital and the like, keys for stop, doctor, comment, and slip are arranged on the front surface of a top cover, and a liquid crystal display is incorporated in the upper stage. A card read-out means 74 is provided. Information in a patient card, a doctor card, and a comment card are read by the means 74 and respectivey stored in appropriate storage means 76, 78, 79. In addition, a bar code printing mode assigning means 82 is provided. When a bar code printing mode is assigned, a patient's ID number in the storage means 76 is converted to a bar code by a conversion means 77. When printing is started by a printing start means 83, the ID number bar code is printed on a label together with time data and a patient's name.
The invention relates to a kit of parts for preparing a glass ionomer cement, the kit comprising a Part A and a Part B, Part A being a powder and comprising an acid-reactive filler in an amount above about 60 wt. %, the acid-reactive filler having a mean particle size in the range of 3.5 to 10 μm, an non acid-reactive filler in an amount above about 1 wt. %, the non acid-reactive filler having a mean particle size in the range of 1.0 to 3.5 μm, Part A not comprising a polyacid in an amount above about 1 wt. %, wt. % with respect to the weight of Part A, Part B being a liquid and comprising a polyacid in an amount above about 30 wt. %, water, a complexing agent, wt. % with respect to the weight of Part B. The invention also relates to a process of producing a hardenable or hardening composition and use thereof in the dental field.
The present invention provides compounds and methods for inhibiting PI 4-kinase. The invention also provides methods of treating pathogen infection and methods of treating cancer. The PI 4-kinase inhibitor may be a 5-aryl or heteroaryl-thiazole compound, e.g., a compound as described herein. In certain embodiments, the PI 4-kinase inhibitor is a substituted 2-amino-5-phenylthiazole or a substituted 2-amino-5-pyridylthiazole compound. In some embodiments, the compounds have broad spectrum anti-infective activity against a variety of infectious diseases, wherein the diseases are caused by a pathogen containing the basic amino acid PIP-2 pincer (BAAPP) domain that interacts with phosphatidylinositol 4, 5-diphosphate (PIP-2) to mediate pathogen replication. The invention also provides methods of treating cancer in a subject using PI 4-kinase inhibitors. Aspects of the methods include inhibiting PI 4-kinase in cancer cells to reduce cell proliferation.
OBJECTIVE: Idiopathic sudden sensorineural hearing loss (ISSNHL), as an otologic emergency, is commonly encountered and its prevalence has been climbing every year recently. To our knowledge, the prognosis of middle-aged and elderly patients is worse than that of young patients. Previous researches mainly focused on the adult population, which was considered as prognostic models who performed hearing recovery in ISSNHL. However, few studies regarding the middle-aged and elderly population who are regarded as prognostic models have been reported. Therefore, we aim to construct and validate a nomogram-based prognostic prediction model, which can provide a reference for the prognostic assessment in the middle-aged and elderly patients with ISSNHL.
METHOD: A total of 371 middle-aged and elderly ISSNHL patients who were admitted to the Department of Otolaryngology-Head and Neck Surgery, Yanbian Hospital, Yanbian University, from April 2018 to April 2023 were enrolled in the study. All subjects were randomly divided into two groups including training group (n = 263) and validation group (n = 108). Lasso regression and multi-factor logistic regression were jointly utilized to screen out prognosis-related independent risk factors and establish a nomogram-based risk prediction model. The accuracy and clinical application value of the model were evaluated by combining the Bootstrapping method and k-fold cross-validation, plotting the receiver operating characteristic  (ROC)  curve, calculating the area under the ROC curve (AUC), plotting the decision curve analysis (DCA), and the calibrating curve.
RESULT: We used the method of lasso regression combined with multivariate logistic regression and finally screened out eight predictors (including age, number of affected ears, degree of hearing loss, type of hearing curve, duration of disease, presence of vertigo, diabetes, and lacunar cerebral infarction) that were included into the nomogram. The C-index were 0.823 [95% CI (0.725, 0.921)] and 0.851 [95% CI (0.701, 1.000)], and the AUC values were 0.812 and 0.823 for the training and validation groups, respectively. The calibration curve for the validation group was approximately conformed to that for the modeling group, indicating favorable model calibration. The DCA results revealed the modeling group (3%-86%) and the validation group (2%-92%) showed significant net clinical benefit under the majority of thresholds.
CONCLUSION: This study developed and validated a nomogram-based prognostic prediction model which based on the eight independent risk factors mentioned above. The predictors are conveniently accessible and may assist clinicians in formulating individualized treatment strategies.